Redesigning chondroitin 6-O-sulfotransferase for efficient whole-cell biosynthesis of chondroitin sulfate C
Bioresource Technology · 2026-06 · 449 · 134397
DOI: 10.1016/j.biortech.2026.134397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioresource Technology, 2026-06. Verfasst von Weiwei Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China; School of Biotechnology and Key Laboratory of Industrial Bio…. Hauptthemen laut MEDLINE: Sulfotransferases, Chondroitin Sulfates, Protein Engineering. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis remains a global health problem and chondroitin sulfate C (CSC) is effective to treat arthritis. The biosynthesis of CSC offers a sustainable and promising alternative to conventional extraction from animal tissues. However, the scarcity of chondroitin-6-O-sulfotransferases and their low catalytic performance have severely hindered the large-scale biosynthesis of CSC. To overcome these limitations, a novel chondroitin-6-O-sulfotransferase from Rattus norvegicus (RnCHST3) was identified via gene fishing, which demonstrates regioselectivity in transferring a sulfate group from 3'-phosphoadenosine-5'-phosphosulfate (PAPS) to the 6-position of chondroitin. Subsequent optimization of expression conditions and truncation of the N-terminal region enhanced the sulfation rate from 4.6% to 11.5%. For the first time, the regioselective mechanism of RnCHST3 was elucidated through molecular dynamics (MD) simulations and site-directed mutagenesis. A mechanism-guided rational design led to the development of mutant M5, which increased the sulfation rate to 46.2%. Furthermore, a novel "physical sieve"-guided PROSS design was developed to improve kinetic thermostability, resulting in mutant M7. This variant exhibited an extended half-life from 9.4 h to 12.3 h and achieved a sulfation rate to 74.5%. Finally, a whole-cell catalytic system was constructed for CSC production, reaching a sulfation rate of 86.4% and a titer of 12.9 g·L-1-the highest level reported to date. This study lays a solid foundation for the industrial biosynthesis of CSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China; School of Biotechnology and Key Laboratory of Industrial Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122,…
- School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
- School of Biotechnology and Key Laboratory of Industrial Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, China.
- School of Biotechnology and Key Laboratory of Industrial Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, China. Electronic address: wanqwei@163.com.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Meng, W., Gao, M., Li, L., Liu, L., Li, X., Wei, W., & Wu, J. (2026). Redesigning chondroitin 6-O-sulfotransferase for efficient whole-cell biosynthesis of chondroitin sulfate C. Bioresource Technology, 449, 134397. https://doi.org/10.1016/j.biortech.2026.134397
Vancouver
Meng W, Gao M, Li L, Liu L, Li X, Wei W, et al. Redesigning chondroitin 6-O-sulfotransferase for efficient whole-cell biosynthesis of chondroitin sulfate C. Bioresource Technology. 2026;449:134397. doi:10.1016/j.biortech.2026.134397
BibTeX
@article{Meng2026,
author = {Meng, Weiwei and Gao, Mengjian and Li, Lulu and Liu, Liming and Li, Xiaomin and Wei, Wanqing and Wu, Jing},
title = {Redesigning chondroitin 6-O-sulfotransferase for efficient whole-cell biosynthesis of chondroitin sulfate C},
journal = {Bioresource Technology},
year = {2026},
volume = {449},
pages = {134397},
doi = {10.1016/j.biortech.2026.134397}
}
EUVIMED